Wall Street’s leadership changed hands over the past month. The technology and chip stocks that carried the market through most of 2026 lost ground, while healthcare, financials, real estate, utilities and consumer-focused stocks took over.
The scoreboard showed it in mid-October. Healthcare led gains among the S&P 500’s 11 sectors and hit a record high, financials rose 1%, real estate climbed 1.7% and utilities added 1.2%, while technology slipped 0.3%. The S&P 500 value index gained 0.9% that day as its growth counterpart dipped 0.2%. Jim Baird, chief investment officer at Plante Moran Financial Advisors, tied the move to doubts about AI payoffs: “Investors are looking for other opportunities outside of tech, and healthcare is one of the beneficiaries of that.”
Tech’s Slide Hands Leadership to Defensive Sectors
The rotation sped up in November. On Monday, investors moved into consumer cyclical, financial services and consumer defensive stocks, and the main technology sector fund was down 2.4% by mid-afternoon. Last Thursday, the Philadelphia Semiconductor Index fell as much as 11%, its worst showing since March 2020, and the Nasdaq Composite slid into a correction, a drop of at least 10% from its record close in early October. The VIX, Wall Street’s fear gauge, jumped more than 65% in a day. In short, money moved toward companies with steadier earnings and away from the most crowded trades.
Sameer Samana, senior global market strategist at Wells Fargo Investment Institute, said the pain was concentrated: “Anything related to AI is down more than anything not related to AI.” Our ranking of stocks sitting near all-time highs that Wall Street favors looks at names that have held up through the swings.
Why Strategists See a Handoff From Growth to Cash Flow
Samana described the shift as a change of buyers. The first wave of AI investors chased growth, he said, while a newer group wants companies with healthy cash flow, and he noted that many AI stocks are still not cheap. Will Compernolle, a macro strategist at FHN Financial, said the selling in chipmakers was sending money into Treasuries, and that investors were also rotating from chipmakers into the biggest spenders on AI data centers.
We covered the group that led October’s gains in our list of healthcare stocks that hedge funds favor. Not everyone reads the selloff as a verdict on the economy. Charlie McElligott, a cross-asset strategist at Nomura, said it reflected hedge funds locking in their 2026 gains rather than a worsening in fundamentals.
Charts
Our Methodology
For this article, we used Finviz to screen for companies with market capitalizations above $2 billion whose stocks are at new all-time highs. We then ranked them by average upside potential, based on analysts’ average price target, in ascending order, as of November 9, 2026. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.
At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
10 Best All-Time High Stocks to Buy According to Wall Street
10. Labcorp (NYSE:LH)
Average Upside Potential: 7%
Share Price: $366.57
Target Price: $392.93
Number of Hedge Fund Holders: 43
Labcorp’s profit is growing about twice as fast as its sales, and management raised its outlook again after the third quarter. Revenue rose 6.9% from a year earlier, while adjusted earnings per share climbed 14.5%. Chairman and Chief Executive Officer Adam Schechter pointed to continued margin expansion behind the gap. The gap shows the gains are not coming from volume alone: the company is keeping more of each dollar it brings in.
The lab operator is also buying more testing volume. It closed its purchase of MLM Medical Labs in the quarter. Since then it has signed agreements to take select BioReference Health lab assets, Myriad Genetics’ prenatal health testing business and Millennium Health, each still waiting on regulatory approval. Cash is paying for much of this: free cash flow came to $412.2 million, up from $280.5 million a year earlier.
Management now expects 2026 adjusted earnings of $18.30 to $18.70 per share, up from a range of $18.10 to $18.55. Whether the discount is worth the cost of all that spending is the question in our look at Labcorp’s earnings discount and growing investment bill.
9. Xometry (NASDAQ:XMTR)
Average Upside Potential: 8%
Share Price: $114.95
Target Price: $124.25
Number of Hedge Fund Holders: 40
Xometry has now grown revenue about 40% for two quarters running, and this time the growth came with a profit. Chief Financial Officer James Miln noted that sales growth held at that pace for the second quarter in a row. Third-quarter revenue reached a record, led by the marketplace side, where buyers post designs for custom parts and manufacturers bid to make them. Sales that grow this fast tend to eat into profit, which is why strong growth that also pays off matters.
The turn to profit is the newer part of the story. The company reported net income of $1.9 million, against a net loss of $11.6 million a year earlier. Chief Executive Officer Sanjeev Singh Sahni said the company’s key growth initiatives drove the record results, and the marketplace’s gross margin also hit a record.
Management lifted its full-year outlook as a result. It now expects revenue growth of at least 37%, up from the 33% to 34% it forecast before, along with adjusted EBITDA of $68 million to $68.5 million for the year. Investors who followed the stock through its loss-making years now have a company that is growing and earning at once.
8. Janus Living (NYSE:JAN)
Average Upside Potential: 8%
Share Price: $31.99
Target Price: $34.62
Number of Hedge Fund Holders: 34
Janus Living’s senior housing communities are fuller than they were a year ago, and residents are paying more per unit. Average occupancy rose by 300 basis points in the third quarter, which helped lift same-store adjusted net operating income by 25.9%. The company calls itself a pure-play senior housing real estate investment trust, so demand for those apartments drives nearly everything it earns. Fuller buildings and higher rents together are what push net operating income up faster than revenue.
It is spending to get bigger while conditions are strong. In the quarter it bought 33 communities for about $1.75 billion, funded in part by an August stock offering. More purchases have closed since quarter-end, and others are under binding agreements to close in the fourth quarter.
Management raised its full-year outlook for FFO as adjusted, a cash earnings measure used by real estate companies, to $0.97 to $0.99 per share, from $0.95 to $0.98. It also lifted its forecast for same-store growth in net operating income, which signals that leaders expect the gains in occupancy and pricing to carry into the final months of the year.
7. American Healthcare REIT (NYSE:AHR)
Average Upside Potential: 9%
Share Price: $57.91
Target Price: $63.69
Number of Hedge Fund Holders: 51
New Chief Financial Officer Aric Chang gave investors a number to hold onto: the company expects its normalized funds from operations per share to grow 31% over 2025 at the midpoint of its raised guidance. The healthcare real estate owner, whose portfolio is mostly senior housing communities, raised that outlook after a third quarter in which its senior housing operating properties posted same-store net operating income growth of 28.2%. A growth rate that high is rare for a real estate owner.
President and Chief Operating Officer Gabe Willhite credited occupancy gains, pricing and expense control for those results. Those are the levers that matter most when residents pay monthly.
The balance sheet gives the company room to keep buying. It acquired 17 senior housing operating assets for about $1.69 billion in the quarter, yet its net debt fell to 1.9 times annualized adjusted EBITDA from 2.5 times at the end of June. Chief Executive Officer Jeff Hanson said the goal is to be the preferred capital partner for top senior housing operators. Lower leverage while buying at that pace is the part worth watching, and it gives management room to keep going.
6. AerCap (NYSE:AER)
Average Upside Potential: 10%
Share Price: $169.64
Target Price: $186.78
Number of Hedge Fund Holders: 61
AerCap sold aircraft at 2.6 times their book value on an equity basis in the third quarter, and it is using the proceeds to shrink its share count. Chief Executive Officer Aengus Kelly said the aircraft lessor delivered another record quarter and raised its guidance. The sale price shows how much buyers are paying for planes in a tight market.
Buybacks are the second half of the story. The company has repurchased more than $2.2 billion of its stock in 2026, about 10% of the shares outstanding at the end of last year, and it announced a new $1 billion repurchase program. Fewer shares means each remaining share claims a larger slice of earnings.
Management now expects full-year adjusted earnings of about $20.70 per share, before any fourth-quarter gains on sales. The balance sheet stays investment grade, with ratings of BBB+ and Baa1 from all three major rating agencies. For a look at its Boeing relationships, see our story on AerCap’s 100th Boeing 787 delivery. Taken together, selling high and buying back stock is the lessor’s way of compounding value for owners.
5. SharkNinja (NYSE:SN)
Average Upside Potential: 10%
Share Price: $222.95
Target Price: $246.09
Number of Hedge Fund Holders: 62
SharkNinja has just stepped into water filtration with the Ninja HydraSense, and the launch shows how the company grows: it takes a product people already buy and sells a new version of it. The same approach is working in the kitchen, where the Ninja Luxe Cafe espresso machine and the Ninja Crispi drove growth in its cooking and beverage business. Each launch gives it another product line to sell through the same retailers and online channels.
Third-quarter net sales rose 21.2% to $1.98 billion, and adjusted net income rose 55.1%, so profit grew much faster than sales. Chief Executive Officer Mark Barrocas summed up the strategy this way: “Scale drives success, and success builds more scale.” That kind of gap usually means a company is adding sales without giving up its margins.
Management raised its fiscal 2026 outlook. It now expects adjusted net income of $6.65 to $6.75 per diluted share, up from $6.45 to $6.55, along with higher sales growth and adjusted EBITDA than it forecast before. Raising the outlook after a quarter like that suggests leaders expect demand to hold into the holiday season.
4. ICICI Bank (NYSE:IBN)
Average Upside Potential: 10%
Share Price: $33.89
Target Price: $37.36
Number of Hedge Fund Holders: 31
ICICI Bank’s profit after tax rose 20.1% to US$1.5 billion in its fiscal second quarter, and the loan book behind it stayed clean: loans classed as non-performing were 1.20% of gross loans at the end of September. It is a rare mix of fast growth and a cleaner book.
Lending is where the growth shows. Excluding loans that its international branches made against foreign-currency deposits, total loans grew 24.1% from a year earlier, and deposits excluding those foreign-currency deposits grew 17.0%. Including them, loans grew 30.0% and deposits 27.1%. Net interest income, the difference between what the bank earns on loans and pays on deposits, grew 17.7% to US$2.6 billion. Growing deposits at that pace gives the bank the cheap funding it needs to keep making loans.
The bank’s net interest margin came in at 4.18%, and its average CASA ratio, the share of its deposits held in lower-cost current and savings accounts, was 35.8%. Those two measures show how cheaply the bank funds its lending while the loan book expands. A wide margin on a growing book is what lets a bank lift profit this quickly.
3. Thermo Fisher Scientific (NYSE:TMO)
Average Upside Potential: 10%
Share Price: $694.76
Target Price: $766.12
Number of Hedge Fund Holders: 118
Thermo Fisher’s newest bet is Precure, a program launched with Mayo Clinic that will combine data from more than one million patient samples with the company’s proteomics tools. It adds a data business to a company best known for lab instruments. Precure is a bet that data from patients can become a repeat business.
The third quarter showed the broader model working. Revenue grew 9% to $12.14 billion. Adjusted earnings per share grew faster, up 15% to $6.68, because the adjusted operating margin widened to 24.5% from 23.3%. Chairman and Chief Executive Officer Marc Casper called it an excellent quarter with outstanding financial performance. Profit rising faster than sales is the sign of a business gaining pricing power and efficiency.
New products keep the pipeline full, including the Orbitrap Isora mass spectrometer and the Ion 560 Chip for its gene sequencing platform. Whether the premium its shares command is deserved is the question in our piece on Thermo Fisher’s valuation and earnings outlook. Fresh products in the instrument and sequencing lines give the company new things to sell to labs and drugmakers.
2. SiriusPoint (NYSE:SPNT)
Average Upside Potential: 11%
Share Price: $26.33
Target Price: $29.25
Number of Hedge Fund Holders: 16
SiriusPoint is about to close the books on the part of its past that has weighed on the business. The insurer agreed to a loss portfolio transfer with RiverStone covering substantially all of its remaining run-off reserves, a deal Chief Executive Officer Scott Egan said will “effectively close the door on this historical book of reserves.” The company expects it to free up more than $200 million of capital once regulators approve it. Ending the run-off also simplifies the story for investors who have had to look past old reserves.
What remains is the business it is building. Core gross written premiums grew 14% in the third quarter, led by its insurance and services unit. The consolidated combined ratio, which compares claims and costs with premiums, was 86.5%. Growth with a combined ratio below 100% means the insurer is earning an underwriting profit on the business it writes.
Book value per diluted common share excluding accumulated other comprehensive income reached $20.21, up 12% from the end of last year. SiriusPoint reports from Hamilton, Bermuda, and net income available to common shareholders for the quarter was $0.74 per diluted share.
1. Liberty Media (NASDAQ:FWONK)
Average Upside Potential: 15%
Share Price: $106.33
Target Price: $122.67
Number of Hedge Fund Holders: 87
Formula 1 President and Chief Executive Officer Stefano Domenicali told investors that every race this season has sold out, with more than half setting attendance records. The numbers from Liberty Media’s third quarter fit that story. Formula 1 revenue rose 28% to $1.12 billion, and adjusted OIBDA, or operating income before depreciation and amortization, jumped 44% to $338 million. The quarter included seven races, compared with six a year earlier. Selling out every race gives the sport pricing power with promoters, broadcasters and sponsors, and the revenue figures show it is being used. Those are the numbers behind the demand story.
Liberty also simplified its ownership. It bought all of the Series B shares held by John Malone and related entities in exchange for Series A and Series C shares, which cut Malone’s voting power to about 3%. The deal closed last week. Chief Executive Officer Derek Chang said Formula 1 continues to deliver exceptional performance and extend its reach. Fewer classes of stock and less concentrated control make Liberty simpler to own and to value. It leaves Liberty with a clearer ownership structure while the sport it owns keeps growing.
READ NEXT: Thermo Fisher (TMO) Is Turning Innovation Into Recurring Revenue. Can Margins Follow? and Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
